TVTX Q1 2022 Earnings — Travere Therapeutics, Inc. Revenue & Financial Results | Market Cap Arena

TVTXTravere Therapeutics, Inc.

$3B

Q1 2022 Earnings

Healthcare Biotechnology

Income Statement

Revenue

$48M+2.3% YoY

Gross Profit

$46M95.6% margin

Operating Income

-$57M-117.7% margin

Net Income

-$76M-156.7% margin

EPS (Diluted)

$-1.20

QoQ Revenue Growth

-15.3%

Cash Flow

Operating Cash Flow

-$55M

Free Cash Flow

-$61M

Stock-Based Comp.

$8M

Balance Sheet

Total Assets

$828M

Total Liabilities

$620M

Stockholders' Equity

$208M

Cash & Equivalents

$257M

Year-over-Year Comparison

Metric	Current	Year Ago	Change
Revenue	$48M	$47M	+2.3%
Gross Profit	$46M	$46M	+1.3%
Operating Income	-$57M	-$48M	-20.0%
Net Income	-$76M	-$54M	-41.0%

Revenue Segments

Product

$46M50%

Bile Acid Products

$25M27%

Tiopronin Products

$21M23%